Authors
CS Bloss, NJ Schork, EJ Topol, DS Ross, CA Lemos-Júnior, A Camargo, R Dey, S Dey, JJ Ross, A Vaidya, UB Kaiser, RT Jensen, G Delle Fave, H Moses III, JB Martin, PJ Orchard, JE Wagner
Publication date
2011/2/10
Description
BACKGROUND
Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.
Scholar articles